v3.25.0.1
SEGMENT REPORTING (Tables)
12 Months Ended
Dec. 31, 2024
SEGMENT REPORTING  
Summary of significant expense categories for the segment

​

​

​

​

​

​

​

​

​

    

Years ended December 31,

​

    

2024

    

2023

Operating expenses:

​

​

​

​

​

​

AV-101 clinical trials

​

$

19,740

​

$

26,548

Employee costs

​

​

19,512

​

​

21,244

Professional fees and services

​

​

11,482

​

​

6,289

Stock-based compensation

​

​

11,311

​

​

11,907

Chemistry, manufacturing, and controls

​

​

11,110

​

​

14,339

Other segment items(a)

​

​

1,515

​

​

1,139

Interest income

​

​

(5,042)

​

​

(5,945)

Consolidated net loss

​

$

69,628

​

$

75,521

​

​

​

​

​

​

​

(a)   Other segment items include rent and facilities related expenses.